PubMed Health⌕ Search

Biomedical subjects

S Lozano

Publications and source records attributed to S Lozano.

5 recordsLinked to original sources
PubMed2002

Management of the female stimulus during semen collection and its association with libido re-establishment and semen characteristics of goats.

The effect of management of the female stimulus during semen collection and its association with libido re-establishment and the semen characteristics of sexually mature goats was evaluated. Eight 2-yr-old bucks were individually subjected to 12 weekly trials in which one of the following three treatments was applied alternately. In treatment one, each male performed two ejaculations on an estrus-induced, restrained doe and semen was collected with an artificial vagina (AV). In treatment two, males were collected as in the former treatment, but a different doe served as the stimulus female for the second ejaculation. In treatment three, two restrained does were present while collecting each buck, allowing males to choose which female to mount and serve in each of the two collections. Number of mounts before first ejaculation and reaction times (period from introduction of the ram to the test arena to his first ejaculation) were similar among treatments (P > 0.05). A significant (P < 0.05) decrease was found for number of mounts performed before achieving the second ejaculation and for latency between ejaculations in the third treatment. No differences (P > 0.05) were found for semen volume (0.8+/-0.03, 1.0+/-0.03, and 0.9+/-0.02 mL) or sperm concentration (4.4+/-0.15, 4.6+/-0.13, and 4.4+/-0.86 spermatozoa/mL) among the three treatments or between the first and second collection. However, a trend to decrease volume and concentration was observed. It was concluded that the simultaneous presence of two females while bucks are collected reduced the number of mounts performed before the second ejaculation and the latency between ejaculations.

Animals↗
PubMed2001

Antifungal activities and cytotoxicity studies of six new azasordarins.

GW 471552, GW 471558, GW 479821, GW 515716, GW 570009, and GW 587270 are members of a new family of sordarin derivatives called azasordarins. The in vitro activities of these compounds were evaluated against clinical isolates of yeasts, including Candida albicans, Candida non-albicans, and Cryptococcus neoformans strains. Activities against Pneumocystis carinii, Aspergillus spp., less common molds, and dermatophytes were also investigated. Azasordarin derivatives displayed significant activities against the most clinically important Candida species, with the exception of C. krusei. Against C. albicans, including fluconazole-resistant strains, MICs at which 90% of the isolates tested are inhibited (MIC(90)s) were 0.002 microg/ml with GW 479821, 0.015 microg/ml with GW 515716 and GW 587270, and 0.06 microg/ml with GW 471552, GW 471558, and GW 570009. The MIC(90)s of GW 471552, GW 471558, GW 479821, GW 515716, GW 570009, and GW 587270 were 0.12, 0.12, 0.03, 0.06, 0.12, and 0.06 microg/ml, respectively, against C. tropicalis and 4, 0.25, 0.06, 0.25, 0.5, and 0.5 microg/ml, respectively, against C. glabrata. In addition, some azasordarin derivatives (GW 479821, GW 515716, GW 570009, and GW 58720) were active against C. parapsilosis, with MIC(90)s of 2, 4, 4, and 1 microg/ml, respectively. The compounds were extremely potent against P. carinii, showing 50% inhibitory concentrations of 16 microg/ml). These azasordarin derivatives also showed significant activity against emerging fungal pathogens, which affect immunocompromised patients, such as Rhizopus arrhizus, Blastoschizomyces capitatus, and Geotrichum clavatum. Against these organisms, the MICs of GW 587270 ranged from 0.12 to 1 microg/ml, those of GW 479821 and GW 515716 ranged from 0.12 to 2 microg/ml, and those of GW 570009 ranged from 0.12 to 4 microg/ml. Against Fusarium oxysporum, Scedosporium apiospermum, Absidia corymbifera, Cunninghamella bertholletiae, and dermatophytes, GW 587270 was the most active compound, with MICs ranging from 4 to 16 microg/ml. Against Aspergillus spp., the MICs of the compounds tested were higher than 16 microg/ml. The in vitro selectivity of azasordarins was investigated by cytotoxicity studies performed with five cell lines and primary hepatocytes. Concentrations of compound required to achieve 50% inhibition of the parameter considered (Tox(50)s) of GW 570009, GW 587270, GW 479281, and GW 515716 in the cell lines ranged from 60 to 96, 49 to 62, 24 to 36, and 16 to 38 microg/ml, respectively. The cytotoxicity values of GW 471552 and GW 471558 were >100 microg/ml for all cell lines tested. Tox(50)s on hepatocytes were in the following order: GW 471558 > GW 471552 > GW 570009 > GW 587270 > GW 515716 > GW 479821, with values ranging from higher than 100 microg/ml to 23 microg/ml. The cytotoxicity results obtained with fully metabolizing rat hepatocytes were in total agreement with those obtained with cell lines. In summary, the in vitro activities against important pathogenic fungi and the selectivity demonstrated in mammalian cell lines justify additional studies to determine the clinical usefulness of azasordarins.

Animals↗
PubMed2000

Use of tissue expanders with external ports.

The high number of reconstructive dilemmas brought about by more aggressive treatment of congenital malformations and burns has created the need for large quantities of donor skin for local coverage. Tissue expansion with external ports has become part of the authors' surgical armamentarium. From January 1996 to November 1998 the authors placed 34 expanders in 28 patients to correct congenital malformations or burn sequelae. The average patient age at the time of operation was 6.3 years, the average time of expansion was 49 days, and minimal and maximal expansion volume was 60 and 600 cc respectively. Serial injection was carried out every 2 days until total expansion was achieved, and the expanded area was two to three times as wide as the recipient defect. No major complications occurred. The most serious complications of infection and erosion of tissue overlying the device occurred in 17.6% of patients. There are several advantages to this technique: less tissue dissection, painless injections, shorter operating time, and early detection of leaks. Lozano ST, Drucker MZ. Use of tissue expanders with external ports.

Adolescent↗